We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
-10.88%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$46.7M
AUM Growth
-$138M
(-75%)
Cap. Flow
-$128M
Cap. Flow
% of AUM
-273.71%
Top 10 Holdings %
Top 10 Hldgs %
69.4%
Holding
38
New
8
Increased
2
Reduced
12
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$3.6M |
| 2 |
DexCom
DXCM
|
+$2.3M |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
+$1.84M |
| 4 |
AMRN
Amarin Corp
AMRN
|
+$1.82M |
| 5 |
Tandem Diabetes Care
TNDM
|
+$1.21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inogen
INGN
|
+$12.8M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$12.5M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$10.5M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$9.79M |
| 5 |
Insmed
INSM
|
+$9.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.36% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$22.7B
| $4.42M | 9.47% |
250,584
-479,856
| -66% | -$9.27M |
|
2
PTC Therapeutics
PTCT
$6.29B
| $4.07M | 8.73% |
120,449
-160,093
| -57% | -$6.97M |
|
|
PTLA
3
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $4.03M | 8.64% |
150,299
-375,431
| -71% | -$10.5M |
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.64M | 7.8% |
75,011
-239,206
| -76% | -$12.5M |
|
5
Gilead Sciences
GILD
$162B
| $3.39M | 7.27% |
53,486
-94,795
| -64% | -$6.2M |
|
|
6
BioMarin Pharmaceuticals
BMRN
$11.6B
| $3.32M | 7.12% |
49,262
-127,063
| -72% | -$9.79M |
|
|
GWPH
7
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $2.73M | 5.85% |
+23,729
| New | +$3.6M |
|
|
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $2.5M | 5.35% |
47,902
-78,753
| -62% | -$4.19M |
|
|
9
DexCom
DXCM
$28.3B
| $2.2M | 4.72% |
+59,080
| New | +$2.3M |
|
10
Natera
NTRA
$37B
| $2.07M | 4.44% |
63,112
-154,787
| -71% | -$4.58M |
|
|
11
Bio-Rad Laboratories Class A
BIO
$8.47B
| $1.88M | 4.02% |
+5,638
| New | +$1.84M |
|
|
XLRN
12
DELISTED
Acceleron Pharma
XLRN
| $1.88M | 4.02% |
47,453
-35,020
| -42% | -$1.52M |
|
|
AMRN
13
Amarin Corp
AMRN
$290M
| $1.58M | 3.4% |
+5,225
| New | +$1.82M |
|
14
CRISPR Therapeutics
CRSP
$4.6B
| $1.52M | 3.26% |
37,141
-60,358
| -62% | -$2.88M |
|
|
ATRS
15
DELISTED
Antares Pharma, Inc.
ATRS
| $1.26M | 2.71% |
377,399
+101,974
| +37% | +$336K |
|
|
NCNA
16
NuCana
NCNA
$5.24M
| $1.19M | 2.55% |
33
+1
| +3% | +$44K |
|
|
17
Tandem Diabetes Care
TNDM
$1.18B
| $1.12M | 2.4% |
+18,995
| New | +$1.21M |
|
18
Verrica Pharmaceuticals
VRCA
$91.9M
| $1.1M | 2.35% |
7,430
-5,852
| -44% | -$652K |
|
19
Twist Bioscience
TWST
$5.39B
| $913K | 1.96% |
38,218
-133,685
| -78% | -$3.89M |
|
|
ARNA
20
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $745K | 1.6% |
+16,272
| New | +$915K |
|
21
Heron Therapeutics
HRTX
$86.9M
| $727K | 1.56% |
+39,273
| New | +$723K |
|
22
Penumbra
PEN
$12.6B
| $363K | 0.78% |
+2,700
| New | +$418K |
|
23
AbbVie
ABBV
$454B
| – | – |
-14,406
| Closed | -$1.05M |
|
24
Adaptive Biotechnologies
ADPT
$3.61B
| – | – |
-22,500
| Closed | -$1.09M |
|
25
Ascendis Pharma A/S
ASND
$16.6B
| – | – |
-3,800
| Closed | -$438K |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q3 2019 Portfolio in Review
As of Q3 2019, Asymmetry Capital Management held 38 positions worth $46.7M, down 75% from $185M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Asymmetry Capital Management withdrew a net $128M in Q3 2019, closing 16 positions and reducing 12 holdings. Its most notable exit was Inogen, an estimated $12.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 90% a quarter earlier, followed by Industrials.
Against the trend, Asymmetry Capital Management opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $2.73M.
- Asymmetry Capital Management's largest Q3 2019 buy was GW Pharmaceuticals Plc American Depositary Shares: 23,729 shares worth $2.73M.
- Asymmetry Capital Management added most to Antares Pharma, Inc. in Q3 2019, an estimated $336K increase.
- Asymmetry Capital Management's biggest Q3 2019 reduction was Global Blood Therapeutics, Inc., cutting an estimated $12.5M.
- Asymmetry Capital Management fully exited Inogen in Q3 2019, selling an estimated $12.8M.
- Asymmetry Capital Management's ten largest holdings make up 69% of its $46.7M portfolio in Q3 2019.
- Asymmetry Capital Management opened 8 new positions and closed 16 in Q3 2019.
- Asymmetry Capital Management's portfolio value fell 75% quarter-over-quarter to $46.7M.
Based on Asymmetry Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.